tradingkey.logo
tradingkey.logo

Twist Bioscience Corp

TWST
33.050USD
-0.530-1.58%
終値 12/26, 16:00ET15分遅れの株価
2.00B時価総額
損失額直近12ヶ月PER

Twist Bioscience Corp

33.050
-0.530-1.58%

詳細情報 Twist Bioscience Corp 企業名

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corpの企業情報

企業コードTWST
会社名Twist Bioscience Corp
上場日Oct 31, 2018
最高経営責任者「CEO」Leproust (Emily M)
従業員数979
証券種類Ordinary Share
決算期末Oct 31
本社所在地681 Gateway Blvd.
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号94080
電話番号18007190671
ウェブサイトhttps://www.twistbioscience.com/
企業コードTWST
上場日Oct 31, 2018
最高経営責任者「CEO」Leproust (Emily M)

Twist Bioscience Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
5.55K
-55.92%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
地域別USD
会社名
収益
比率
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
事業別
地域別
事業別USD
会社名
収益
比率
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
他の
54.46%
株主統計
株主統計
比率
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
他の
54.46%
種類
株主統計
比率
Investment Advisor
66.18%
Investment Advisor/Hedge Fund
36.08%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.69%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
Artisan Partners Limited Partnership
6.41M
10.62%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
State Street Investment Management (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
詳細を見る
ARK Genomic Revolution ETF
比率6.24%
iShares Genomics Immunology and Healthcare ETF
比率3.92%
Global X Genomics & Biotechnology ETF
比率2.09%
ROBO Global Healthcare Technology & Innovation ETF
比率2%
WisdomTree BioRevolution Fund
比率1.79%
ARK Innovation ETF
比率1.47%
Franklin Genomic Advancements ETF
比率1.17%
State Street SPDR S&P Biotech ETF
比率0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率0.66%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.56%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Twist Bioscience Corpの上位5名の株主は誰ですか?

Twist Bioscience Corpの上位5名の株主は以下のとおりです。
ARK Investment Management LLCは6.40M株を保有しており、これは全体の10.60%に相当します。
Artisan Partners Limited Partnershipは6.41M株を保有しており、これは全体の10.62%に相当します。
The Vanguard Group, Inc.は5.82M株を保有しており、これは全体の9.64%に相当します。
BlackRock Institutional Trust Company, N.A.は4.86M株を保有しており、これは全体の8.05%に相当します。
William Blair Investment Management, LLCは3.91M株を保有しており、これは全体の6.47%に相当します。

Twist Bioscience Corpの株主タイプ上位3種は何ですか?

Twist Bioscience Corpの株主タイプ上位3種は、
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.

Twist Bioscience Corp(TWST)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Twist Bioscience Corpの株式を保有している機関は566社あり、保有株式の総市場価値は約71.88Mで、全体の119.09%を占めています。2025Q2と比較して、機関の持ち株は2.37%増加しています。

Twist Bioscience Corpの最大の収益源は何ですか?

FY2025Q3において、NGS tools部門がTwist Bioscience Corpにとって最大の収益を生み出しており、その金額は55.28Mで、全収益の57.55%を占めています。
KeyAI